These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 22095251)

  • 41. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
    Zhang JP; Malhotra AK
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):9-37. PubMed ID: 21162693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalized pharmacotherapy in psychiatry.
    Filaković P; Petek A
    Psychiatr Danub; 2009 Sep; 21(3):341-6. PubMed ID: 19794353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
    de Leon J
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):532-4. PubMed ID: 26088654
    [No Abstract]   [Full Text] [Related]  

  • 44. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
    Bousman CA; Jaksa P; Pantelis C
    Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implementation and utilization of genetic testing in personalized medicine.
    Abul-Husn NS; Owusu Obeng A; Sanderson SC; Gottesman O; Scott SA
    Pharmgenomics Pers Med; 2014; 7():227-40. PubMed ID: 25206309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenetics: from discovery to patient care.
    Shin J; Kayser SR; Langaee TY
    Am J Health Syst Pharm; 2009 Apr; 66(7):625-37. PubMed ID: 19299369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacogenetics. Clinical relevance in anesthsiology].
    Zeidler EM; Goetz AE; Zöllner C
    Anaesthesist; 2013 Nov; 62(11):874-86. PubMed ID: 24275933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variant discovery using next-generation sequencing and its future role in pharmacogenetics.
    Russell LE; Schwarz UI
    Pharmacogenomics; 2020 May; 21(7):471-486. PubMed ID: 32338137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
    Kalman LV; Agúndez J; Appell ML; Black JL; Bell GC; Boukouvala S; Bruckner C; Bruford E; Caudle K; Coulthard SA; Daly AK; Del Tredici A; den Dunnen JT; Drozda K; Everts RE; Flockhart D; Freimuth RR; Gaedigk A; Hachad H; Hartshorne T; Ingelman-Sundberg M; Klein TE; Lauschke VM; Maglott DR; McLeod HL; McMillin GA; Meyer UA; Müller DJ; Nickerson DA; Oetting WS; Pacanowski M; Pratt VM; Relling MV; Roberts A; Rubinstein WS; Sangkuhl K; Schwab M; Scott SA; Sim SC; Thirumaran RK; Toji LH; Tyndale RF; van Schaik R; Whirl-Carrillo M; Yeo K; Zanger UM
    Clin Pharmacol Ther; 2016 Feb; 99(2):172-85. PubMed ID: 26479518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.
    Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ
    Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
    Quaranta S; Dupouey J; Colle R; Verstuyft C
    Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical application of pharmacogenetics: focusing on practical issues.
    Chang MT; McCarthy JJ; Shin J
    Pharmacogenomics; 2015; 16(15):1733-41. PubMed ID: 26411302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addressing the challenges of the clinical application of pharmacogenetic testing.
    Ikediobi ON; Shin J; Nussbaum RL; Phillips KA; ; Walsh JM; Ladabaum U; Marshall D
    Clin Pharmacol Ther; 2009 Jul; 86(1):28-31. PubMed ID: 19536122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies.
    Holmes MV; Shah T; Vickery C; Smeeth L; Hingorani AD; Casas JP
    PLoS One; 2009 Dec; 4(12):e7960. PubMed ID: 19956635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?
    de Leon J; Spina E
    Expert Rev Clin Pharmacol; 2016; 9(3):351-4. PubMed ID: 26580456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenetic screening and therapeutic drugs.
    Steimer W; Potter JM
    Clin Chim Acta; 2002 Jan; 315(1-2):137-55. PubMed ID: 11728416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
    Lauschke VM; Ingelman-Sundberg M
    Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.